mitotam

Mitotam is a novel mitochondrially targeted anticancer drug derived from tamoxifen, linked with triphenylphosphonium (TPP⁺) to facilitate accumulation in the mitochondria of cancer cells. Its design enables selective delivery of tamoxifen into the mitochondrial matrix, leading to efficient disruption of mitochondrial function; specifically, it inhibits respiratory complex I (NADH:ubiquinone dehydrogenase), disrupts respiratory supercomplexes, collapses mitochondrial membrane potential, increases reactive oxygen species production, and triggers cancer cell death. Unlike tamoxifen, it is effective against treatment-resistant tumors—including those with high HER2 levels—and exhibits low toxicity toward normal cells. Mitotam has shown significant efficacy, particularly in metastatic renal cell carcinoma, and has undergone phase I/Ib clinical trials. It is also being considered for age-related disorders due to its selective elimination of senescent cells[1][2][3][4].

Other names

mitochondrially targeted tamoxifen